Sanofi $SNY Shares Purchased by NewEdge Wealth LLC

NewEdge Wealth LLC boosted its holdings in Sanofi (NASDAQ:SNY) by 63.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 67,303 shares of the company’s stock after buying an additional 26,035 shares during the period. NewEdge Wealth LLC’s holdings in Sanofi were worth $3,298,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Financial Consulate Inc. acquired a new stake in shares of Sanofi in the third quarter worth $26,000. First Horizon Corp purchased a new stake in Sanofi during the 3rd quarter worth $33,000. Salomon & Ludwin LLC increased its holdings in Sanofi by 1,046.3% in the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after purchasing an additional 701 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Sanofi by 233.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock valued at $48,000 after purchasing an additional 700 shares in the last quarter. Finally, Traub Capital Management LLC purchased a new position in Sanofi in the second quarter valued at about $51,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on SNY. Barclays downgraded Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. TD Cowen restated a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Sanofi presently has an average rating of “Hold” and an average target price of $62.67.

Sanofi Stock Performance

Sanofi stock opened at $46.76 on Friday. The company has a current ratio of 1.09, a quick ratio of 0.29 and a debt-to-equity ratio of 0.20. The stock has a 50 day moving average of $47.55 and a 200-day moving average of $48.55. The stock has a market cap of $114.05 billion, a P/E ratio of 12.99, a price-to-earnings-growth ratio of 1.23 and a beta of 0.45. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.